These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071 [TBL] [Abstract][Full Text] [Related]
4. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Weinstein AM; Giraldo NA; Petitprez F; Julie C; Lacroix L; Peschaud F; Emile JF; Marisa L; Fridman WH; Storkus WJ; Sautès-Fridman C Cancer Immunol Immunother; 2019 Jan; 68(1):109-120. PubMed ID: 30315348 [TBL] [Abstract][Full Text] [Related]
5. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Li R; Berglund A; Zemp L; Dhillon J; Putney R; Kim Y; Jain RK; Grass GD; Conejo-Garcia J; Mulé JJ Front Immunol; 2021; 12():694079. PubMed ID: 34267760 [TBL] [Abstract][Full Text] [Related]
6. A B-cell or a key player? The different roles of B-cells and antibodies in melanoma. Rodgers CB; Mustard CJ; McLean RT; Hutchison S; Pritchard AL Pigment Cell Melanoma Res; 2022 May; 35(3):303-319. PubMed ID: 35218154 [TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722 [TBL] [Abstract][Full Text] [Related]
9. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Willsmore ZN; Harris RJ; Crescioli S; Hussein K; Kakkassery H; Thapa D; Cheung A; Chauhan J; Bax HJ; Chenoweth A; Laddach R; Osborn G; McCraw A; Hoffmann RM; Nakamura M; Geh JL; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Papa S; Barber L; Lacy KE; Karagiannis SN Front Immunol; 2020; 11():622442. PubMed ID: 33569063 [TBL] [Abstract][Full Text] [Related]
10. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors. Flippot R; Teixeira M; Rey-Cardenas M; Carril-Ajuria L; Rainho L; Naoun N; Jouniaux JM; Boselli L; Naigeon M; Danlos FX; Escudier B; Scoazec JY; Cassard L; Albiges L; Chaput N J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631710 [TBL] [Abstract][Full Text] [Related]
11. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123 [TBL] [Abstract][Full Text] [Related]
12. Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Rodriguez AB; Peske JD; Engelhard VH Methods Mol Biol; 2018; 1845():241-257. PubMed ID: 30141017 [TBL] [Abstract][Full Text] [Related]
13. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer. Sakimura C; Tanaka H; Okuno T; Hiramatsu S; Muguruma K; Hirakawa K; Wanibuchi H; Ohira M J Surg Res; 2017 Jul; 215():74-82. PubMed ID: 28688665 [TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
15. High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment. Barros LRC; Souza-Santos PT; Pretti MAM; Vieira GF; Bragatte MAS; Mendes MFA; De Freitas MV; Scherer NM; De Oliveira IM; Rapozo DCM; Fernandes PV; Simão TA; Soares-Lima SC; Boroni M; Ribeiro Pinto LF; Bonamino MH J Leukoc Biol; 2020 Oct; 108(4):1307-1318. PubMed ID: 32827331 [TBL] [Abstract][Full Text] [Related]
16. Designed Methods for the Sorting of Tertiary Lymphoid Structure-Immune Cell Populations. Devi-Marulkar P; Kaplon H; Dieu-Nosjean MC; Lawand M Methods Mol Biol; 2018; 1845():189-204. PubMed ID: 30141014 [TBL] [Abstract][Full Text] [Related]
17. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. van Hooren L; Vaccaro A; Ramachandran M; Vazaios K; Libard S; van de Walle T; Georganaki M; Huang H; Pietilä I; Lau J; Ulvmar MH; Karlsson MCI; Zetterling M; Mangsbo SM; Jakola AS; Olsson Bontell T; Smits A; Essand M; Dimberg A Nat Commun; 2021 Jul; 12(1):4127. PubMed ID: 34226552 [TBL] [Abstract][Full Text] [Related]
20. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment. Li H; Li J; Zhang C; Zhang C; Wang H Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]